Actively Recruiting
A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer
Led by The First Affiliated Hospital of Air Force Medicial University · Updated on 2025-09-30
3
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if Autologous Drug-Loaded Neutrophils (NeuMed) can treat patients with Unresectable Pancreatic Cancer. The drug carried by the Autologous Neutrophils is Monomethyl Auristatin E. The main questions it aims to answer are: First, to verify the safety of Autologous Drug-Loaded Neutrophils (NeuMed) in patients with Unresectable Pancreatic Cancer. Second, to assess the anti-tumor efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in patients with Unresectable Pancreatic Cancer.
CONDITIONS
Official Title
A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged between 18 and 70 years
- Provide voluntary informed consent
- Diagnosis of unresectable pancreatic cancer confirmed by histopathology
- Have either received standard first-line treatments with no success or intolerable side effects, or have not received such treatments and choose NeuMed therapy
- Eastern Cooperative Oncology Group (ECOG) score of 2 or less and expected survival of at least 3 months
- Liver, kidney, and bone marrow functions are basically normal
You will not qualify if you...
- Require anti-coagulant therapy
- Have active infections or a history of bone marrow or organ transplantation
- Have autoimmune or autoinflammatory diseases
- Have severe cardiovascular or cerebrovascular diseases, interstitial lung disease, or non-infectious pneumonia
- Have received live vaccines within 30 days prior to enrollment
- Show no response to bone marrow mobilization
- Are considered unsuitable for enrollment by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of the PLA Air Force Military Medical University
Xi’an, Shanxi, China, 710000
Actively Recruiting
Research Team
L
Liang Jin, Doctor of Medicine(M.D.)
CONTACT
L
Lin Wang, Doctor of Medicine(M.D.)
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here